<DOC>
	<DOCNO>NCT00538902</DOCNO>
	<brief_summary>A study ass safety efficacy adalimumab administer subcutaneous injection adult Chinese subject rheumatoid arthritis treat methotrexate</brief_summary>
	<brief_title>Safety Efficacy Study Adalimumab Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate</brief_title>
	<detailed_description>This multi-center , Phase 2/3 , randomize , double-blind ( DB ) , parallel group , placebo control , safety efficacy study adult Chinese RA subject . The duration study approximately 116 week . This include 4-week ( 28 day ) Screening period , 12-week Double-Blind ( DB ) period , 90-week Open-Label ( OL ) Period , 10-week ( 70 day ) Follow-up period . The 70-day Safety Follow-up period initiate last dose study medication . During DB period , 302 Chinese subject RA concomitantly treat MTX enrol 11 clinical site locate throughout China . Subjects randomly assign one three treatment group 2:2:1 ratio : 80 mg adalimumab , 40 mg adalimumab , placebo . From Week 0 Week 10 , subject receive blinded study drug . Subjects successfully participate complete Week 12 DB portion study participate OL period . All subject OL period receive adalimumab 40 mg . Throughout study , study drug administer subcutaneously ( SC ) every week ( eow ) . Subjects complete Week 24 visit , prior approval Protocol Amendment 1 , 70 day last dose study drug re-enter study . The Investigator confirm subject develop exclusion criterion complete procedure define OL Screening visit . Results Week 24 study present regulatory dossier marketing authorization application Humira China , fulfil requirement clinical data Chinese patient . However , order continue provide treatment patient respond well adalimumab , subject option continue OL extension study Week 92 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Met ACR criterion diagnosis active rheumatoid arthritis ( RA ) Screening visit Week 0 visit least four swollen joint ( 66 assess ) least six tender joint ( 68 assess ) Subjects must fail prior treatment one diseasemodifying antirheumatic drug ( DMARDs ) DMARDs ( methotrexate [ MTX ] ) must discontinue &gt; = 28 day least 5 halflives , whichever great , Week 0 visit Traditional Chinese Medicines must discontinue &gt; = 28 day Week 0 visit Subjects must receive least three month treatment MTX ( minimum 7.5 mg/week ) remain stable dose MTX &gt; = 28 day prior Screening visit Glucocorticoids equivalent &lt; = 10 mg prednisone prednisone equivalent must remain unchanged least 28 day prior Week 0 visit Must able willing give write informed consent comply requirement study protocol A history , current , acute inflammatory joint disease different origin ( e.g. , mixed connective tissue disease , seronegative spondyloarthropathy , psoriatic arthritis , Reiter 's syndrome , systemic lupus erythematosus , fibromyalgia arthritide onset prior age 16 year Wheelchairbound bedridden Joint surgery involve joint assess within study , within two month prior Screening visit Intraarticular , intramuscular intravenous administration corticosteroid within 28 day prior Screening visit Prior treatment TNF antagonist , include adalimumab Subject consider investigator , reason , unsuitable candidate Female subject pregnant breastfeeding consider become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Humira , methotrexate</keyword>
</DOC>